Lintusumab-Ac225 is about to enter phase I/II clinical trials in combination with Cytarabine for older patients with untreated acute myeloid leukaemia (AML) [294] and actinium-225-labelled humanized anti-CD33 monoclonal antibody HuM195 is completing phase I trials for patients with advanced myeloid malignancies [295]. The gene discussed is CD33; the disease is acute myeloid leukemia.